6 results
Primary objective1. To demonstrate the efficacy of at least one of three doses of ACT-128800 as compared to placebo in patients withrelapsing-remitting multiple sclerosis (RRMS) on the cumulative number of new gadolinium-enhancing lesionsper patient…
Primary Objective: *To evaluate the immune responses 1 month after 3 doses of 13vPnC as measured by fold rises of serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) in subjects *2 years of age. Secondary Objectives: *To…
Primary Objective: • To determine the efficacy of 13vPnC in preventing a first episode of self-reported ILI.Secondary Objectives: • To determine the efficacy of 13vPnC in preventing a first episode of self-reported LRTI.• To determine the incidence…
Primary Objective: • To determine the incidence rate of self-reported ILI.Secondary Objectives: • To determine the efficacy of 13vPnC in preventing a first episode of self-reported LRTI.• To explore the effect of 13vPnC on the incidence of self-…
Primary Safety Objective: To describe the safety profile of 20vPnC
To assess the safety and tolerability ofBNT141 at different dose levels.To identify the maximum tolerated dose (MTD) or maximally administered dose (MAD) /recommended Phase IIdose (RP2D) of BNT141 based on theoccurrence of dose-limiting toxicities(…